Teva Launches First Generic Of Sun’s Absorica In US
Company Also Launched Erythromycin Tablets In US
Executive Summary
Teva has launched the first US generic version of Absorica (isotretinoin), expanding its dermatological portfolio. The company has also launched generic erythromycin tablets in the US. Meanwhile, in its recent environmental, social and governance progress report, Teva has launched a plan to increase access to medicines globally by 2025.
You may also be interested in...
Sun Wants To Join The Biosimilars Party, In Time
India's Sun Pharma is to foray into biosimilars, targeting first approval status for “third wave” products. It trails several peers and the changed stance comes as biosimilars gain traction in markets including the US, where experts have predicted a “coming out party” in the next few years.
What’s Next? Five Things To Look Out For In June
In June, the $6bn Organon business, including a healthy biosimilars operation, will begin trading, while Coherus BioSciences aims to file for biosimilar Lucentis with partners Formycon and Bioeq.
Teva Launches First US Generic Of Retrophin’s Thiola
Teva has launched the first US generic version of Thiola (tiopronin) tablets in the US, shortly after launching first generic versions of isotretinoin capsules and generic oerythromycin tablets.